I-MAB SPONS.ADS/1 -0001 Asset Resilience Ratio

Latest as of December 2025: 0.08%

I-MAB SPONS.ADS/1 -0001 asset resilience ratio. I-MAB SPONS.ADS/1 -0001 (0VY) has an Asset Resilience Ratio of 0.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See I-MAB SPONS.ADS/1 -0001 (0VY) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€210.00K
≈ $245.51K USD Cash + Short-term Investments

Total Assets

€260.52 Million
≈ $304.58 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of I-MAB SPONS.ADS/1 -0001 (2021–2025)

Asset resilience ratio of I-MAB SPONS.ADS/1 -0001 from 2021 to 2025. This chart shows how I-MAB SPONS.ADS/1 -0001's Asset Resilience Ratio has changed over time. Read I-MAB SPONS.ADS/1 -0001 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down I-MAB SPONS.ADS/1 -0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see I-MAB SPONS.ADS/1 -0001 balance sheet assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €210.00K 0.08%
Total Liquid Assets €210.00K 0.08%

Asset Resilience Insights

  • Limited Liquidity: I-MAB SPONS.ADS/1 -0001 maintains only 0.08% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

I-MAB SPONS.ADS/1 -0001 Industry Peers by Asset Resilience Ratio

Compare I-MAB SPONS.ADS/1 -0001's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
Biotechnology 35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294
Biotechnology 23.15%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Achieve Life Sciences Inc
F:SP4P
Biotechnology 3.60%

I-MAB SPONS.ADS/1 -0001 Asset Resilience Ratio by Year (2021–2025)

I-MAB SPONS.ADS/1 -0001 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for I-MAB SPONS.ADS/1 -0001.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.08% €210.00K
≈ $245.51K
€260.52 Million
≈ $304.58 Million
-49.35pp
2024-12-31 49.43% €105.14 Million
≈ $122.91 Million
€212.68 Million
≈ $248.65 Million
+43.95pp
2023-12-31 5.48% €20.22 Million
≈ $23.64 Million
€368.92 Million
≈ $431.31 Million
-0.30pp
2022-12-31 5.78% €34.12 Million
≈ $39.89 Million
€590.45 Million
≈ $690.29 Million
-7.67pp
2021-12-31 13.45% €118.16 Million
≈ $138.14 Million
€878.74 Million
≈ $1.03 Billion
--
pp = percentage points

About I-MAB SPONS.ADS/1 -0001

F:0VY Germany Biotechnology
Market Cap
$141.97 Million
€121.43 Million EUR
Market Cap Rank
#17690 Global
#1658 in Germany
Share Price
€1.05
Change (1 day)
-1.87%
52-Week Range
€1.05 - €4.46
All Time High
€70.00
About

NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more